Photocure ASA: Exercise of employee share options
2020-12-01 16:02:15
Oslo, Norway, 1 December 2020: Reference is made to the stock exchange
release<br />
by Photocure ASA ("Photocure" or the "Company") published on 30 November 2020<br
/>
regarding exercise of share options.<br />
<br />
The price for option shares sold by primary insiders have been determined at
a<br />
price of NOK 79.0128 per share.<br />
<br />
The primary insiders having exercised options have purchased shares in
Photocure<br />
at a price per share of NOK 79.0128 as follows:<br />
<br />
· Erik Dahl, CFO, has purchased 7,189 shares. Following completion of the<br
/>
purchase, Erik Dahl holds, directly or indirectly, 20,222 shares, 35,000<br />
conditional share options and 40,000 share options in the Company.<br />
· Grete Hogstad, VP Strategic Marketing, has purchased 5,032 shares.
Following<br />
completion of the purchase, Grete Hogstad holds, directly or indirectly,
26,876<br />
shares, 25,000 conditional share options and 25,000 share options in the<br />
Company.<br />
· Gry Stensrud, VP Technical Development and Operation, has purchased
12,553<br />
shares. Following completion of the purchase, Gry Stensrud holds, directly or<br
/>
indirectly, 22,442 shares, 25,000 conditional share options and 18,750 share<br
/>
options in the Company.<br />
<br />
For further information, please contact:<br />
<br />
Photocure CFO Erik Dahl<br />
Tel: +47 450 55 000<br />
Email: ed@photocure.com<br />
<br />
About Photocure ASA<br />
<br />
Photocure: The Bladder Cancer Company delivers transformative solutions to<br />
improve the lives of bladder cancer patients. Our unique technology, making<br
/>
cancer cells glow bright pink, has led to better health outcomes for patients<br
/>
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo<br
/>
Stock Exchange (OSE: PHO). For more information, please visit us at<br />
www.photocure.com, www.hexvix.com, www.cysview.com<br />
<br />
This information is subject to the disclosure requirements pursuant to
sections<br />
5-12 and 4-2 of the Norwegian Securities Trading Act.